Find Funding Opportunities

Returning 168 results

BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trials Not Allowed)

RFA
Wednesday, October 4, 2017
Wednesday, December 12, 2018
R01
RFA-EB-17-003

Funding Opportunity Purpose

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new and novel noninvasive human brain imaging technologies and methods that will lead to transformative advances in our understanding of the human brain. The FOA solicits unusually bold and potentially transformative approaches and supports small-scale, proof-of-concept development based on exceptionally innovative, original and/or unconventional concepts.

NIH SIREN Neurologic Clinical Trials (U01 Clinical Trial Required)

PAR
Tuesday, October 3, 2017
Friday, January 8, 2021
U01
PAR-18-304

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols.

NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44)

PAR
Monday, September 11, 2017
Translational Research
Sunday, September 6, 2020
R44
PAR-17-480

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects requiring approval from a Federal regulatory agency or for those projects developing complex research tools. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NIHs SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.

NINDS CREATE Bio Optimization Track for Biologics (U01)

PAR
Monday, August 14, 2017
Translational Research
Tuesday, September 8, 2020
U01
PAR-17-456
Chris Boshoff

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).

NINDS CREATE Bio Optimization Track for Biologics (U44)

PAR
Monday, August 14, 2017
Translational Research
Tuesday, September 8, 2020
U44
PAR-17-457
Chris Boshoff

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) supports SBIRs in the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track.

Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)

PA
Tuesday, August 1, 2017
Tuesday, September 8, 2020
R21
PA-17-446

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)

PA
Tuesday, August 1, 2017
Tuesday, September 8, 2020
R01
PA-17-444

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)

PA
Friday, July 28, 2017
Wednesday, October 16, 2019
333
PA-17-442

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384 and subsequent reissuances)

Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supplement)

PA
Tuesday, July 18, 2017
Thursday, September 19, 2019
333
PA-17-326

Funding Opportunity Purpose

The National Institutes of Health (NIH) announces the continuation of the U.S. entity of the U.S.-Japan Brain Research Cooperative Program (BRCP). This administrative supplement program will provide funds to research projects that are currently supported by the participating NIH Institutes and Centers.

NINDS Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25)

PAR
Monday, June 12, 2017
Thursday, September 26, 2019
R25
PAR-17-312

Funding Opportunity Purpose

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NINDS Neuroscience Development for Advancing the Careers of a Diverse Research Workforce R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by (1) increasing the pool of current and future Ph.D.-level research scientists from diverse backgrounds underrepresented in biomedical neuroscience research; and (2) facilitating the career advancement/transition of the participants to the next step of their neuroscience careers.

Pages